Real-world outcomes of advanced melanoma patients not represented in phase III trials
Source: MDLinx, October 2020
Researchers sought to provide evidence on systemically treated patients with advanced melanoma not represented in phase III trials to support clinical decision–making.
Between 2014 and 2017, analysis were conducted on advanced melanoma patients diagnosed in the Netherlands, treated with immune– or targeted therapy, who met ≥ 1 trial exclusion criteria.
Such criteria were obtained from the KEYNOTE–006 and CHECKMATE–067/–066 phase III trials.
